In recognition of their variable morphologies but homogeneous dark zone biologic features and gene expression characteristics, the WHO-HAEM5 renames the entity diffuse large B-cell lymphoma/high-grade B-cell lymphoma withMYCandBCL2rearrangements (DLBCL/HGBL-MYC/BCL2) to encompass tumours defined by the presence of dual MYC and BCL2 rearrangements that may be composed of large or intermediate or blastoid cells (Fig. 4). Here, MYC is linked to diffuse large B-cell lymphoma.